DE69940899D1 - AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung - Google Patents

AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung

Info

Publication number
DE69940899D1
DE69940899D1 DE69940899T DE69940899T DE69940899D1 DE 69940899 D1 DE69940899 D1 DE 69940899D1 DE 69940899 T DE69940899 T DE 69940899T DE 69940899 T DE69940899 T DE 69940899T DE 69940899 D1 DE69940899 D1 DE 69940899D1
Authority
DE
Germany
Prior art keywords
convection
production
aav vectors
methods
raav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940899T
Other languages
English (en)
Inventor
Krys Bankiewicz
Janet Cunningham
Jamie Eberling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Genzyme Corp
Original Assignee
University of California
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Genzyme Corp filed Critical University of California
Application granted granted Critical
Publication of DE69940899D1 publication Critical patent/DE69940899D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y401/00Carbon-carbon lyases (4.1)
    • C12Y401/01Carboxy-lyases (4.1.1)
    • C12Y401/01028Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
DE69940899T 1998-05-27 1999-05-26 AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung Expired - Lifetime DE69940899D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8694998P 1998-05-27 1998-05-27
US13474899P 1999-05-18 1999-05-18

Publications (1)

Publication Number Publication Date
DE69940899D1 true DE69940899D1 (de) 2009-06-25

Family

ID=26775343

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69940899T Expired - Lifetime DE69940899D1 (de) 1998-05-27 1999-05-26 AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
DE69941100T Expired - Lifetime DE69941100D1 (de) 1998-05-27 1999-05-26 AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
DE69929600T Expired - Lifetime DE69929600T2 (de) 1998-05-27 1999-05-26 Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69941100T Expired - Lifetime DE69941100D1 (de) 1998-05-27 1999-05-26 AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
DE69929600T Expired - Lifetime DE69929600T2 (de) 1998-05-27 1999-05-26 Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren

Country Status (9)

Country Link
US (7) US6309634B1 (de)
EP (1) EP1080202B1 (de)
JP (2) JP2002516295A (de)
AT (3) ATE435917T1 (de)
CA (1) CA2329259C (de)
DE (3) DE69940899D1 (de)
ES (3) ES2257051T3 (de)
PT (1) PT1080202E (de)
WO (1) WO1999061066A2 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215422A1 (en) 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
EP1080202B1 (de) * 1998-05-27 2006-01-25 Avigen, Inc. Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
ES2313784T3 (es) * 1998-05-28 2009-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Vector aav5 y usos del mismo.
US6855314B1 (en) * 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US7672712B2 (en) * 2000-03-30 2010-03-02 The Regents Of The University Of Michigan Internal marker device for identification of biological substances
US7098374B2 (en) 2001-02-09 2006-08-29 University Of Florida Research Foundation, Inc. Human disease modeling using somatic gene transfer
US7588757B2 (en) * 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
EP1469730A4 (de) * 2001-10-30 2006-02-01 Verfahren und zusammensetzungen zur behandlung der parkinson-krankheit
US7419817B2 (en) * 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US7090836B2 (en) 2002-06-21 2006-08-15 Institut Pasteur Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal
US20050143330A1 (en) * 2002-09-30 2005-06-30 Ron Mandel Method for the treatment of Parkinson's Disease
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
PL378110A1 (pl) * 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
US8946151B2 (en) * 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7963956B2 (en) 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
US8927269B2 (en) 2003-05-19 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Avian adenoassociated virus and uses thereof
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
RU2005138368A (ru) 2003-06-10 2006-07-27 ЭнЭсДЖЕНЕ А/С (DK) Улучшенная секреция нейбластина
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
NZ547185A (en) 2003-10-20 2009-03-31 Nsgene As In vivo gene therapy of parkinson's disease
WO2005056807A2 (en) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32
US20080188431A1 (en) * 2004-09-08 2008-08-07 Chiorini John A Transcytosis of Adeno-Associated Viruses
PT1807009E (pt) 2004-10-05 2015-02-25 Univ California Cânula escalonada
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
US8283151B2 (en) * 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US20060257912A1 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
US8524678B2 (en) 2005-05-31 2013-09-03 The Regents Of The University Of Colorado, A Body Corporate Method for delivering genes
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US9089667B2 (en) * 2005-08-23 2015-07-28 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US20070132284A1 (en) * 2005-12-06 2007-06-14 Albert Ekladyous Headliner mounted center high mount stop lamp (chmsl)
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
JP6105187B2 (ja) * 2006-04-25 2017-03-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cns障害の処置のための成長因子の投与
EP2023949A4 (de) * 2006-04-26 2009-08-26 Univ California Zusammensetzungen und verfahren für konvektionsverstärkte freisetzung von neurotherapeutika mit hohem molekulargewicht
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
CA2654498A1 (en) * 2006-06-06 2007-12-21 Avigen, Inc. Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
WO2008033285A2 (en) * 2006-09-15 2008-03-20 The Trustees Of Culumbia University In The City Of New York Delivery of double-stranded rna into the central nervous system
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US7819842B2 (en) * 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US20080171906A1 (en) * 2007-01-16 2008-07-17 Everaerts Frank J L Tissue performance via hydrolysis and cross-linking
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
EP1970001B1 (de) * 2007-03-16 2014-07-23 Brainlab AG Katheter mit Drucksensorik
US20090036395A1 (en) * 2007-04-26 2009-02-05 Davidson Beverly L Rna interference suppression of neurodegenerative diseases and methods of use thereof
EP2152346B1 (de) * 2007-05-17 2015-12-02 Medgenesis Therapeutix Inc. Konvektionsverstärkter abgabekatheter mit entfernbarem versteifungsglied
EP2530152B1 (de) * 2007-05-31 2017-12-27 University of Iowa Research Foundation Reduktion der Off-Target-RNA-Interferenztoxizität
US20100284984A1 (en) * 2007-07-30 2010-11-11 University Of Rochester Adenosine and its mimetics. modulators, transport inhibitors, and receptor agonists as a therapeutic tool to replace or improve the efficacy of deep brain stimulation
EP2187898B8 (de) * 2007-09-12 2016-09-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung viraler vektoren, die das cyp46a1 gen tragen, für die behandlung der alzheimer krankheit
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
CN102027133A (zh) * 2008-05-07 2011-04-20 温瑟瑞克斯有限公司 鉴定调节癌细胞中Wnt信号传导的化合物的方法
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
BRPI1007155A2 (pt) 2009-01-29 2017-05-30 Univ Of California San Francisco métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata
SI2424991T1 (sl) 2009-05-02 2018-11-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
MX358980B (es) * 2009-08-25 2018-09-11 The Regents Of The Univ Of California Star Colocacion optimizada de canula para suministro de terapeuticos al cerebro.
NZ600104A (en) 2009-11-09 2013-11-29 Genepod Therapeutics Ab Novel viral vector construct for neuron specific optimized continuous DOPA synthesis in vivo
EP2558154B1 (de) 2010-04-16 2020-06-17 ClearPoint Neuro, Inc. Chirurgisches mrt-system mit mrt-kompatiblen chirurgischen kanülen zur übertragung einer substanz in den oder aus dem körper eines patienten
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US10130687B2 (en) 2011-01-05 2018-11-20 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
US9181544B2 (en) 2011-02-12 2015-11-10 University Of Iowa Research Foundation Therapeutic compounds
US20120220648A1 (en) * 2011-02-24 2012-08-30 National Taiwan University Hospital Method of Treating Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using Adeno-Associated Virus (AAV)-AADC Vector
JP6007463B2 (ja) * 2011-04-18 2016-10-12 国立研究開発法人国立精神・神経医療研究センター 薬剤送達粒子及びその製造方法
WO2013019830A2 (en) 2011-08-01 2013-02-07 Alcyone Lifesciences, Inc. Microfluidic drug delivery devices
KR102075881B1 (ko) 2011-09-05 2020-02-11 호바 세라퓨틱스 에이피에스 이질통, 통각과민증, 자발통 및 환상통의 치료
WO2013155152A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
TW201412304A (zh) * 2012-08-17 2014-04-01 Teva Pharma 瑞沙吉林之非經腸調配物
EP2934627B1 (de) 2012-12-18 2021-04-07 Alcyone Lifesciences, Inc. Vorrichtungen und verfahren zur verminderung oder verhinderung von rückstrom in einem abgabesystem
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CA3209821A1 (en) 2013-05-15 2014-11-20 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
CN110215595B (zh) 2013-06-17 2022-04-12 亚克安娜治疗学有限公司 导管末梢保护系统和立体定向固定装置
JP6498670B2 (ja) 2013-07-31 2019-04-10 アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. 薬剤送達、治療、およびモニタリングのためのシステムおよび方法
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
EP3046586B1 (de) 2013-09-19 2021-07-07 The Regents of The University of California Behandlungsverfahren mit bis-polymer-lipidpeptid-konjugaten und nanopartikeln daraus
KR20160147974A (ko) 2014-05-02 2016-12-23 젠자임 코포레이션 망막 및 cns 유전자 요법을 위한 aav 벡터
RU2711147C2 (ru) 2014-05-20 2020-01-15 Юниверсити Оф Айова Рисерч Фаундейшн Терапевтические соединения для лечения болезни хантингтона
US10758484B2 (en) 2014-08-25 2020-09-01 Nippon Kayaku Co., Ltd. CED of SN-38-loaded micelles against brain tumor
CN107073051B (zh) * 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
CN107106689A (zh) * 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
US11242374B2 (en) 2015-01-22 2022-02-08 Brown University Minimally-invasive and activity-dependent control of excitable cells
US10806396B2 (en) 2015-01-26 2020-10-20 Alcyone Lifesciences, Inc. Drug delivery methods with tracer
HUE057272T2 (hu) * 2015-02-10 2022-04-28 Genzyme Corp Vírusrészecskék fokozott bevitele a csíkolt testbe és az agykéregbe
CN106190949B (zh) * 2015-05-08 2020-04-10 上海微创心通医疗科技有限公司 一种干态动物源性胶原纤维组织材料及其制备方法和生物假体
US20190032079A1 (en) 2015-08-03 2019-01-31 Myodopa Limited Systemic synthesis and regulation of l-dopa
IL258030B (en) 2015-09-23 2022-08-01 Sangamo Therapeutics Inc Htt suppressing factors and their uses
CN108472019A (zh) 2016-01-04 2018-08-31 亚克安娜生命科学有限公司 用于治疗中风的方法和装置
EP3393571B1 (de) 2016-02-17 2024-03-06 ClearPoint Neuro, Inc. Chirurgische intrabody-flüssigkeitstransferanordnungen mit verstellbarer freiliegender kanüle zur nadelspitzenlänge, zugehörige systeme und verfahren
CA3019427A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2017198839A1 (en) 2016-05-20 2017-11-23 Vihinen Mauno Destabilising domains for conditionally stabilising a protein
CN110650673A (zh) 2016-08-30 2020-01-03 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
WO2018071831A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
CA3043635A1 (en) 2016-12-01 2018-06-07 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
US11179411B2 (en) 2017-05-18 2021-11-23 Kyoto University Composition for prevention or treatment of spinocerebellar ataxia type 36
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
SG11202002457RA (en) 2017-09-22 2020-04-29 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
BR112020013994A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
EP3781074A1 (de) 2018-05-09 2021-02-24 ClearPoint Neuro, Inc. Mrt-kompatible intrakorporale flüssigkeitsübertragungssysteme und zugehörige vorrichtungen und verfahren
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
TW202012628A (zh) * 2018-05-15 2020-04-01 美商航海家醫療公司 用於帕金森氏症治療的組成物及方法
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
EP4333872A1 (de) 2021-05-06 2024-03-13 Hoba Therapeutics ApS Vorbeugung und behandlung von chemotherapie-induzierten neuropathischen schmerzen
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
JP2514913B2 (ja) * 1987-10-19 1996-07-10 忠三 岸本 ヒトbcdfを含有する神経系障害治療剤
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5766948A (en) * 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
EP0755454B1 (de) 1994-04-13 2008-02-13 The Rockefeller University Aav-vermittelte überbringung von dna in zellen des nervensystems
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6103226A (en) 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
US5599706A (en) * 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US5667158A (en) 1995-05-23 1997-09-16 Glaxo Wellcome Inc. Automated blend reclaim system for pharmaceutical tablet compression machine
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
AU3591597A (en) * 1996-06-28 1998-01-21 Regents Of The University Of California, The Transformation and genetherapy of cells of the inner ear
JPH1113A (ja) 1997-06-12 1999-01-06 Mitsubishi Agricult Mach Co Ltd 乗用農機
EP1080202B1 (de) * 1998-05-27 2006-01-25 Avigen, Inc. Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren

Also Published As

Publication number Publication date
US20160256534A1 (en) 2016-09-08
US20100104537A1 (en) 2010-04-29
EP1080202B1 (de) 2006-01-25
WO1999061066A2 (en) 1999-12-02
WO1999061066A9 (en) 2000-03-30
DE69929600T2 (de) 2006-09-07
US9492415B2 (en) 2016-11-15
US8309355B2 (en) 2012-11-13
ES2326893T3 (es) 2009-10-21
US20130101510A1 (en) 2013-04-25
PT1080202E (pt) 2006-05-31
US20050180955A1 (en) 2005-08-18
US6953575B2 (en) 2005-10-11
US7534613B2 (en) 2009-05-19
ES2257051T3 (es) 2006-07-16
ES2324540T3 (es) 2009-08-10
US20180243249A1 (en) 2018-08-30
CA2329259A1 (en) 1999-12-02
EP1080202A2 (de) 2001-03-07
US6309634B1 (en) 2001-10-30
DE69929600D1 (de) 2006-04-13
ATE435917T1 (de) 2009-07-15
WO1999061066A3 (en) 2000-05-04
DE69941100D1 (de) 2009-08-20
JP2006298926A (ja) 2006-11-02
ATE316576T1 (de) 2006-02-15
CA2329259C (en) 2003-08-05
US20020141980A1 (en) 2002-10-03
JP2002516295A (ja) 2002-06-04
ATE431418T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
DE69941100D1 (de) AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
ATE465267T1 (de) Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen
DK0764213T3 (da) Vektorer der koder for rekombinante AAV-genomer
JP2021534809A (ja) Aavカプシドの向性の再指向化
Gouel et al. Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates
DE60315009D1 (de) Zusammensetzungen zur verabreichung von enzymen involviert im aminosäuremetabolismus durch verwendung rekombinanter adeno-assoziierter virus vironen (raav vironen), und methode und verwendung zur behandlung von aminosäuremetabolischen störungen unter verwendung solcher raav vironen
Zheng et al. Lentiviral vectors and adeno‐associated virus vectors: useful tools for gene transfer in pain research
RU2020137429A (ru) Лечение пигментного ретинита
FI962990A0 (fi) Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä
RU2018115760A (ru) Генетическая конструкция
WO2000046246A8 (en) Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
ES2062993T3 (es) Factor de crecimiento humano i semejante a la preproinsulina.
FR2717824B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
MX2022002961A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
MX2021010134A (es) Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn.
CN113631225A (zh) 用于生产aav颗粒的方法和系统
JP2020533968A (ja) 組換えアデノ随伴ベクター
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
WO2015148454A1 (en) Optimized and modified factor viii genes for gene therapy
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
MX2022002960A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
UY38881A (es) Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept
PL1664315T3 (pl) Wektory aav do terapii genowej in vivo reumatoidalnego zapalenia stawów
WO2001090189A3 (en) G-protein coupled receptor org3.
Bowles et al. 1064. Haute Couture Vectors: Solving Clinical Problems with Custom Designed AAV Vectors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition